dm+d
Unassigned
New Medicines
Fabry's disease in adults and children - second-line
Information
New molecular entity
Chiesi
Protalix
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Pre-registration (Filed)
Yes
Category
Alpha-galactosidase replacement
Fabry disease affects approximately 5,000 to 10,000 people worldwide, but may be under diagnosed
Fabry's disease in adults and children - second-line
Intravenous infusion
Further information
Yes
To be confirmed